

Statement regarding use of non-GAAP financial measures

In this press release, the Company's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company's core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company's business. A reconciliation of the GAAP financial results to non-GAAP financial results is included in the attached schedules.

The Company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Non-GAAP financial results are reported in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.

**Reconciliation of GAAP to Non-GAAP Financial Measures
for the three and six months ended December 31, 2020**

(Unaudited data in millions, except per share amount)

| | Three Months Ended | | Six Months Ended | |
|---|--------------------|-------------------|-------------------|-------------------|
| | December 31, 2020 | December 31, 2019 | December 31, 2020 | December 31, 2019 |
| <i>Revenue</i> | \$ 154.6 | \$ 195.1 | \$ 299.8 | \$ 381.4 |
| GAAP Cost of molecular diagnostic testing | \$ 42.6 | \$ 41.0 | 82.5 | 82.2 |
| GAAP Cost of pharmaceutical and clinical services | 4.5 | 8.6 | 8.8 | 17.1 |
| Equity compensation | (0.4) | (0.4) | (0.8) | (0.7) |
| Transformation initiatives | (0.4) | — | (0.4) | (0.2) |
| Non-GAAP COGS | \$ 46.3 | \$ 49.2 | \$ 90.1 | \$ 98.4 |
| Non-GAAP Gross Margin | 70.1% | 74.8% | 69.9% | 74.2% |
| GAAP Research and Development | \$ 18.2 | \$ 18.8 | \$ 35.8 | \$ 40.1 |
| Equity compensation | (1.1) | (1.2) | (2.3) | (2.7) |
| Transformation initiatives | (0.5) | (0.3) | (0.5) | (1.0) |
| Other adjustments | (0.4) | — | (0.7) | — |
| Non-GAAP Research and Development | \$ 16.2 | \$ 17.3 | \$ 32.3 | \$ 36.4 |
| GAAP Contingent Consideration | \$ 4.6 | \$ (0.1) | \$ 3.5 | \$ 0.6 |
| Other adjustments | (4.6) | 0.1 | (3.5) | (0.6) |
| Non-GAAP Contingent Consideration | \$ — | \$ — | \$ — | \$ — |
| GAAP Impairment of Goodwill and Intangibles | \$ — | \$ 1.3 | \$ — | \$ 1.3 |
| Impairment of goodwill and intangibles | — | (1.3) | — | (1.3) |
| Non-GAAP Impairment of Goodwill and Intangibles | \$ — | \$ — | \$ — | \$ — |
| GAAP Selling, General and Administrative | \$ 132.9 | \$ 134.3 | \$ 257.0 | \$ 269.8 |
| Acquisition - amortization of intangible assets | (15.2) | (15.2) | (30.4) | (30.4) |
| Equity compensation | (5.1) | (5.5) | (11.8) | (12.5) |
| Transformation initiatives | (8.0) | (2.1) | (9.9) | (4.4) |
| Other adjustments | (1.2) | (1.3) | (4.0) | (1.9) |
| Non-GAAP Selling, General and Administrative | \$ 103.4 | \$ 110.2 | \$ 200.9 | \$ 220.6 |
| GAAP Operating Loss | \$ (48.2) | \$ (8.8) | \$ (87.8) | \$ (29.7) |
| Acquisition - amortization of intangible assets | 15.2 | 15.2 | 30.4 | 30.4 |
| Impairment of goodwill and intangibles | — | 1.3 | — | 1.3 |
| Equity compensation | 6.6 | 7.1 | 14.9 | 15.9 |
| Transformation initiatives | 8.9 | 2.4 | 10.8 | 5.6 |
| Other adjustments | 6.2 | 1.2 | 8.2 | 2.5 |
| Non-GAAP Operating Income (Loss) | \$ (11.3) | \$ 18.4 | \$ (23.5) | \$ 26.0 |
| Non-GAAP Operating Margin | -7.3% | 9.4% | -7.8% | 6.8% |
| GAAP Net Loss Attributable to Myriad Genetics, Inc. Stockholders | \$ (44.2) | \$ (8.3) | \$ (59.4) | \$ (28.9) |
| Acquisition - amortization of intangible assets | 15.2 | 15.2 | 30.4 | 30.4 |
| Impairment of goodwill and intangibles | — | 1.3 | — | 1.3 |
| Equity compensation | 6.6 | 7.1 | 14.9 | 15.9 |
| Transformation initiatives | 8.9 | 2.4 | 10.8 | 5.6 |
| Other adjustments | 11.7 | 1.3 | 15.8 | 2.5 |
| Non-GAAP tax benefit adjustment | (7.6) | (1.4) | (32.4) | (3.3) |
| Non-GAAP Net Income (Loss) | \$ (9.4) | \$ 17.6 | \$ (19.9) | \$ 23.5 |
| GAAP Diluted Loss per Share | \$ (0.59) | \$ (0.11) | \$ (0.79) | \$ (0.39) |
| Non-GAAP Diluted Earnings (Loss) per Share | \$ (0.12) | \$ 0.24 | \$ (0.27) | \$ 0.32 |
| <i>Diluted shares outstanding</i> | 75.3 | 74.4 | 75.0 | 74.1 |

Free Cash Flow Reconciliation
(Unaudited data in millions)

| | Three Months Ended | | Six Months Ended | |
|---|--------------------|-------------------|-------------------|-------------------|
| | December 31, 2020 | December 31, 2019 | December 31, 2020 | December 31, 2019 |
| GAAP cash flows from operations | \$ (13.7) | \$ (1.9) | \$ (73.0) | \$ 13.9 |
| Capital expenditures | (6.7) | (3.4) | (8.2) | (4.8) |
| Free cash flow | \$ (20.4) | \$ (5.3) | \$ (81.2) | \$ 9.1 |
| Transformation initiative costs | 8.9 | 2.4 | 10.8 | 5.6 |
| Settlement of hereditary cancer Qui Tam compliant | — | 9.1 | — | 9.1 |
| Other adjustments | 6.3 | 1.3 | 8.5 | 1.9 |
| Tax effect associated with non-GAAP adjustments | (3.6) | (3.0) | (4.5) | (2.1) |
| Non-GAAP Free cash flow | \$ (8.8) | \$ 4.5 | \$ (66.4) | \$ 23.6 |

Following is a description of the adjustments made to GAAP financial measures:

- Acquisition – amortization of intangible assets: Represents recurring amortization charges resulting from the acquisition of intangible assets, including developed technology and database rights
- Equity compensation – non-cash equity-based compensation provided to Myriad employees
- Transformation initiatives – transitory costs related to Myriad's Elevate 2020 program and transformation initiatives
- Other – Other one-time non-recurring expenses including expenses related to leadership transition, COVID-19 costs, non-recurring legal expenses, and potential future consideration related to acquisitions, and the non-cash impact of foreign exchange transactions
- Non-GAAP tax expense/(benefit) adjustment – Tax expense/(benefit) due to non-GAAP adjustments, ASU 2016-09 employee share-based payment accounting, and CARES Act legislation.